Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.
Stryjewski ME, Graham DR, Wilson SE, O'Riordan W, Young D, Lentnek A, Ross DP, Fowler VG, Hopkins A, Friedland HD, Barriere SL, Kitt MM, Corey GR; Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study. Stryjewski ME, et al. Among authors: barriere sl. Clin Infect Dis. 2008 Jun 1;46(11):1683-93. doi: 10.1086/587896. Clin Infect Dis. 2008. PMID: 18444791 Clinical Trial.
Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.
Stryjewski ME, O'Riordan WD, Lau WK, Pien FD, Dunbar LM, Vallee M, Fowler VG Jr, Chu VH, Spencer E, Barriere SL, Kitt MM, Cabell CH, Corey GR; FAST Investigator Group. Stryjewski ME, et al. Among authors: barriere sl. Clin Infect Dis. 2005 Jun 1;40(11):1601-7. doi: 10.1086/429914. Epub 2005 Apr 28. Clin Infect Dis. 2005. PMID: 15889357 Clinical Trial.
Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study.
Stryjewski ME, Chu VH, O'Riordan WD, Warren BL, Dunbar LM, Young DM, Vallée M, Fowler VG Jr, Morganroth J, Barriere SL, Kitt MM, Corey GR; FAST 2 Investigator Group. Stryjewski ME, et al. Among authors: barriere sl. Antimicrob Agents Chemother. 2006 Mar;50(3):862-7. doi: 10.1128/AAC.50.3.862-867.2006. Antimicrob Agents Chemother. 2006. PMID: 16495243 Free PMC article. Clinical Trial.
Genotypic characteristics of Staphylococcus aureus isolates from a multinational trial of complicated skin and skin structure infections.
Campbell SJ, Deshmukh HS, Nelson CL, Bae IG, Stryjewski ME, Federspiel JJ, Tonthat GT, Rude TH, Barriere SL, Corey R, Fowler VG Jr. Campbell SJ, et al. Among authors: barriere sl. J Clin Microbiol. 2008 Feb;46(2):678-84. doi: 10.1128/JCM.01822-07. Epub 2007 Dec 12. J Clin Microbiol. 2008. PMID: 18077636 Free PMC article.
Presence of genes encoding the panton-valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: results of a multinational trial.
Bae IG, Tonthat GT, Stryjewski ME, Rude TH, Reilly LF, Barriere SL, Genter FC, Corey GR, Fowler VG Jr. Bae IG, et al. Among authors: barriere sl. J Clin Microbiol. 2009 Dec;47(12):3952-7. doi: 10.1128/JCM.01643-09. Epub 2009 Oct 21. J Clin Microbiol. 2009. PMID: 19846653 Free PMC article. Clinical Trial.
Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.
Rubinstein E, Lalani T, Corey GR, Kanafani ZA, Nannini EC, Rocha MG, Rahav G, Niederman MS, Kollef MH, Shorr AF, Lee PC, Lentnek AL, Luna CM, Fagon JY, Torres A, Kitt MM, Genter FC, Barriere SL, Friedland HD, Stryjewski ME; ATTAIN Study Group. Rubinstein E, et al. Among authors: barriere sl. Clin Infect Dis. 2011 Jan 1;52(1):31-40. doi: 10.1093/cid/ciq031. Clin Infect Dis. 2011. PMID: 21148517 Free PMC article. Clinical Trial.
TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections.
Stryjewski ME, Potgieter PD, Li YP, Barriere SL, Churukian A, Kingsley J, Corey GR; TD-1792 Investigators Group. Stryjewski ME, et al. Among authors: barriere sl. Antimicrob Agents Chemother. 2012 Nov;56(11):5476-83. doi: 10.1128/AAC.00712-12. Epub 2012 Aug 6. Antimicrob Agents Chemother. 2012. PMID: 22869571 Free PMC article. Clinical Trial.
137 results